Cannabis in bipolar disorder

TL;DR

• Gibbs 2015 meta-analysis: OR 2.97 for mania with cannabis use.
• Cannabis shortens the euthymic phase.
• CBD preclinical (Poleg 2019): anti-manic effects in animal models.
• No clinical recommendation — cannabis destabilises mood.

Why THC destabilises

THC drives mesolimbic dopaminergic pathways — in bipolar I patients this can trigger manic switches, especially when mood stabilisers are stopped.

Neurobiological vulnerability and the endocannabinoid system

The endocannabinoid system plays a central role in regulating emotions, stress responses, and synaptic plasticity. In individuals with bipolar disorder, an altered density and sensitivity of cannabinoid receptors, particularly the CB1 receptor in the prefrontal cortex and the limbic system, is suspected. When exogenous cannabinoids such as THC interfere with this sensitive balance, it can disrupt the body's own homeostasis. Instead of the desired calming effect, overstimulation of the receptors often leads to a dysregulation of neurotransmitters such as glutamate and gamma-aminobutyric acid (GABA), which intensifies emotional instability.

Another critical aspect is the influence of THC on the circadian system and sleep architecture. Bipolar disorders are closely linked to disruptions of the sleep-wake cycle, with sleep deprivation being a known trigger for manic episodes. Although cannabis use can facilitate falling asleep in the short term, it fragments sleep in the medium term and reduces REM phases. This chronic sleep disturbance further destabilizes neuronal resilience. The combination of disrupted synaptic transmission and impaired sleep quality drastically increases susceptibility to affective fluctuations and complicates therapeutic stabilization.

• Dysregulation of the CB1 receptor in emotion-processing brain regions
• Imbalance of excitatory and inhibitory neurotransmitters caused by exogenous THC
• Disruption of the circadian rhythm and long-term deterioration of sleep quality
• Increased neuronal vulnerability to psychosocial stress

Swiss legal framework and practice in psychiatric diagnoses

In Switzerland, the prescription of medical cannabis has been possible since August 2022 without an exceptional authorization from the Federal Office of Public Health (FOPH). The responsibility lies entirely with the treating physicians. However, there is great reluctance regarding psychiatric conditions such as bipolar disorder. Due to the inherent risk of manic switches and psychotic symptoms, bipolar disorder is considered a relative to absolute contraindication for THC-rich preparations in medical practice. Swissmedic monitors the authorization of corresponding medicinal products, while cantonal authorities govern enforcement.

Strict exclusion criteria also apply to the ongoing Swiss pilot trials for the regulated distribution of cannabis, such as in Zurich or Basel. Individuals with severe psychiatric diagnoses, including bipolar disorders, are excluded from participation in order to prevent health crises. Furthermore, a strict zero-tolerance policy applies to road traffic, with a limit of 1.5 micrograms of THC per litre of blood. Since cannabis consumption additionally impairs fitness to drive in bipolar patients due to cognitive impairment, non-compliance carries a risk of significant legal consequences and the withdrawal of the driving licence.

• Medical cannabis prescribable without a BAG exceptional permit since August 2022
• Bipolar disorder as a contraindication for THC-containing therapies in practice
• Exclusion of bipolar individuals from the cantonal cannabis pilot trials
• Strict limit of 1.5 µg/L of blood in Swiss road traffic

The paradox of self-medication and clinical supervision

Many affected individuals turn to cannabis during depressive phases or times of inner restlessness to independently alleviate symptoms such as anxiety, lack of drive, or insomnia. However, this form of self-medication carries a major paradox: while consumption is perceived as relieving in the short term, it worsens the course of the illness in the long term. The apparent relief masks the progressive destabilisation of the nervous system. Furthermore, consumption complicates the therapeutic alliance, as symptoms are often misinterpreted and the willingness to take prescribed mood stabilisers such as lithium or anticonvulsants decreases.

Professional clinical support therefore relies on an open, non-judgmental anamnesis and targeted psychoeducation. Affected individuals must understand how cannabinoids interact with their specific neurobiology. Rather than pure prohibitions, the focus is on developing risk awareness and alternative coping strategies. If complete abstinence is not acutely possible, harm reduction strategies must be discussed. This includes education about the dangers of synthetic cannabinoids, which can trigger unpredictable crises, as well as the involvement of emergency contacts such as Tox Info Suisse in the event of acute intoxication.

• Short-term subjective relief contradicts long-term instability
• Risk of interactions and reduced medication adherence
• Importance of psychoeducation and harm reduction in therapy
• Risk from unregulated synthetic cannabinoid compounds on the black market

FAQ